James Kihara - 23 Feb 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: Principal Accounting Officer
Signature: /s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol: ACAD
Transactions as of: 23 Feb 2022
Net transactions value: -$8,544
Form type: 4
Filing time: 25 Feb 2022, 16:45:58 UTC
Previous filing: 19 Nov 2021
Next filing: 07 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise	$0	+840		$0.000000	840	23 Feb 2022	Direct
transaction	ACAD	Common Stock	Sale	$8,544	-359	-43%	$23.80	481	23 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	+840	+50%	$0.000000	2,520	23 Feb 2022	Common Stock	840		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3	The restricted stock units vest in four equal annual installments beginning February 23 2022.